Lineage Cell Therapeutics, Inc. (LCTX) is a publicly traded Healthcare sector company. As of September 8, 2026, LCTX trades at $1.11 with a market cap of $273.14M and a P/E ratio of -7.71. LCTX moved +2.59% today. Year to date, LCTX is -35.33%; over the trailing twelve months it is -11.48%. Its 52-week range spans $0.37 to $2.09. Analyst consensus is strong buy with an average price target of $7.00. Rallies surfaces LCTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest LCTX news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $1.11 |
| Market Cap | $273.14M |
| P/E Ratio | -7.71 |
| EPS | $-0.14 |
|---|
| Dividend Yield | 0.00% |
|---|
| 52-Week High | $2.09 |
|---|
| 52-Week Low | $0.37 |
|---|
| Volume | 131.11K |
|---|
| Avg Volume | 0 |
|---|
| Revenue (TTM) | $13.08M |
|---|
| Net Income | $-32.10M |
|---|
| Gross Margin | 0.00% |
|---|
4 analysts cover LCTX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.00.